#SFHS2611915AFrance Expands Public-Sector Coverage for Nintedanib Arrow in Pediatric Lung Disease
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
France expands public-sector coverage for two Nintedanib Arrow capsule presentations, 100 mg and 150 mg, to cover additional pediatric indications involving serious progressive interstitial lung diseases. The change affects hospitals, public health services, prescribers, pharmacists, and eligible children and adolescents aged 6 to 17. It means these medicines can now be used under the approved public-sector medicines list for the newly added indications.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Extends public-sector coverage for Nintedanib Arrow 100 mg capsules.
- Extends public-sector coverage for Nintedanib Arrow 150 mg capsules.
- Adds pediatric indications for progressive fibrosing interstitial lung disease and systemic sclerosis-associated interstitial lung disease.
Obligations
What this law requires
Public-sector health establishments and services must apply the amended approved medicines list so that NINTEDANIB ARROW 100 mg and 150 mg capsule presentations are covered for children and adolescents aged 6 to 17 with clinically significant progressive fibrosing diffuse interstitial lung diseases.
Public-sector health establishments and services must apply the amended approved medicines list so that NINTEDANIB ARROW 100 mg and 150 mg capsule presentations are covered for children and adolescents aged 6 years and older with diffuse interstitial lung disease associated with systemic sclerosis.
Prescribers and pharmacists in public-sector care settings must limit use under this public-sector approved medicines listing to the two listed NINTEDANIB ARROW presentations: CIP 34009 303 229 0 1, 100 mg capsules, and CIP 34009 303 229 5 6, 150 mg capsules.